Navigation Links
Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007
Date:9/6/2007

income (loss) 4,047 (18,378) 7,722 (7,103)

Other income (expense), net (1,744) (641) 126 (831)

Equity in loss of joint venture (166) (121) (663) (534)

Net investment gain 3,190 - (583) 16,013

Interest income 2,919 1,506 8,974 5,343

Interest expense (1,712) (1,553) (6,781) (6,793)

Income from continuing

operations before provision

(benefit) for income taxes 6,534 (19,187) 8,795 6,095

Provision (benefit) for income

taxes 1,489 (8,491) 2,054 (5,726)

Income (loss) from continuing

operations 5,045 (10,696) 6,741 11,821

Discontinued operations:

Loss from discontinued operations - (1,548) - (4,957)

Loss from disposal - (38,018) - (38,018)

Benefit for income taxes - (14,549) - (15,845)

Loss from discontinued operations - (25,017) - (27,130)

Net income (loss) $5,045 $(35,713) $6,741 $(15,309)

Basic earnings (loss) per share

of common stock:

Income (loss) from continuing

operations $0.15 $(0.31) $0.20 $ 0.35

Loss from discontinued operations - (0.73) - (0.79)

Net income (loss) $0.15 $(1.04) $0.20 $(0.44)

Diluted earnings (loss) per

share of common stock:

Income (loss) from continuing

operations $0.15 $(0.31) $0.19 $ 0.35

Loss from discontinued

operations - (0.73) - (0.79)

Net income (loss) $0.15 $(1.04) $0.19 $(0.44)

Weighted average number of


'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. South Africa Wins landmark case against pharmaceutical giants
2. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
3. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
4. Setting up a new pharmaceutical industry in India
5. Medicis Pharmaceutical company enters pediatric market
6. Supply of Radiopharmaceuticals Hampered by Attacks
7. Pharmaceutical companies are targeting patients
8. FDA approves Watson Pharmaceuticals Oxytrol patch
9. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
10. Indian Pharmaceutical Industries Stops Manufacturing And Sale Of Valdecoxib
11. Pharmaceutical industries grant for R&D to be monitored
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2015)... ... August 01, 2015 , ... ... L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy & Wellness (“Premier”) — ... portfolio of state-of-the-art clinics. , “Our acquisition of Premier Physical Therapy & Wellness ...
(Date:8/1/2015)... ... August 01, 2015 , ... “ reTXT ” was featured on NewsWatch ... coolest applications on the market for iOS, Android, and Windows. Joe Toohey, the host ... users to clarify, edit and delete any message including ones already sent. , While ...
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot and ... new type of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) for ... commemorate introduction of this new type of sod, Super-Sod is giving away red Adirondack ...
(Date:7/31/2015)... ... July 31, 2015 , ... Precision Aesthetics is New York’s only ... was also the first provider of Exilis non-surgical fat reduction in New York. ... has attracted a large International clientele. Many patients travel to New York to ...
(Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics ... this week. Zeltiq Aesthetics released this new applicator in the United States as ... treating the outer thighs. The original applicator required a 2 hour treatment time. ...
Breaking Medicine News(10 mins):Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
... there are differences in pathological subtypes of multiple sclerosis ... sclerosis (MS) patients with evidence for antibody deposition or ... tissue destruction -- in their lesions are likely to ... attacks. ,The research findings will be published ...
... following the water borne diseases crossed 55 even as the ... 55 dead were from the densely populated city suburbs that ... 1,000 patients had been admitted to various Mumbai hospitals with ... hospitals in this city of over 15 million people had ...
... men who report feeling nervous and anxious are nine ... perceive themselves as relaxed. Their research findings were published ... and Community Health., ,The findings are based on ... representative face-to-face survey of 16 to 74 year olds, ...
... risk of developing breast cancer increase manifold has been challenged. ... Institute, used the latest data to estimate a woman’s individual ... in relation to hormone replacement therapy. This is known as ... a woman’s risk of developing breast cancer while taking hormone ...
... a tracer chemical, monamine oxidase (MAO), which will help those struggling ... crucial role in blood pressure and mood regulation // has two ... levels of MAO B in smokers' peripheral organs - the heart, ... percent compared to non-smokers. , , The results of tracking ...
... capitalists will soon start selling donated mothers' milk to ... ,The company, Prolacta, will offer regular and high-fat ... ,The milk will be collected by donor nursing ... be frozen and shipped to Prolacta's California headquarters for ...
Cached Medicine News:Health News:Different Types Of Multiple Sclerosis May Be Treated Differently 2Health News:HRT Not That Risky For Breast Cancer 2Health News:Donated Mothers Milk To Hit The Market 2
(Date:7/30/2015)... -- Amgen (NASDAQ: AMGN ) today announced financial ... results include: , Total revenues increased 4 ... $5,370 million, with 6 percent product sales growth ... ® (denosumab), Sensipar ® (cinacalcet), Kyprolis ... Unfavorable changes in foreign exchange rates impacted total ...
(Date:7/30/2015)... , July 30, 2015 Tianyin Pharmaceutical Inc. ... company that specializes in the patented biopharmaceutical, modernized traditional ... (API), provided updates regarding the notice it received on ... "Exchange") indicating that the Company was below certain of ... Sections 134 and 1101 of the NYSE MKT Company ...
(Date:7/30/2015)... N.J. , July 30, 2015  Growth of ... switches as they bring former prescription users to the ... Kline forecasts robust Rx-to-OTC switch activity over ... categories emerging along with many new brands entering the ... occur over the next five years (even those with ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... 94 Percent of Men Maintained Normal Testosterone Levels Throughout ... ... 92 Percent of Men Expressed Satisfaction with NEBIDO, LEXINGTON, Mass., ... data on NEBIDO(R),(testosterone undecanoate), an investigational, long-acting intramuscular,injection for the treatment of ...
... Del., May 20 A new 12-week,study(2) ... maintenance,combination asthma therapy, SYMBICORT(R) (budesonide/formoterol fumarate,dehydrate) Inhalation ... in children ages 6 to 15 years ... corticosteroid (ICS).(2) Of note, the study included,efficacy ...
Cached Medicine Technology:Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association 2Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association 3Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association 4Study Analyzed SYMBICORT(R) in Children with Persistent Asthma 2Study Analyzed SYMBICORT(R) in Children with Persistent Asthma 3Study Analyzed SYMBICORT(R) in Children with Persistent Asthma 4Study Analyzed SYMBICORT(R) in Children with Persistent Asthma 5
... autoLog™ Autotransfusion System processes blood collected ... washed red blood cells for return ... time. This is achieved with only ... innovative bowl design, coupled with sophisticated ...
The hipGRIP® is a twenty piece modular lateral positioning system which provides positive pelvis control with an innovative positioning system....
The Simpulse®VariCare™ System provides an innovative system for enhanced wound management which emphasizes performance, simplicity, safety, value, and support....
... staples are especially useful in ... including anterior cruciate reconstruction. They ... fixation, tendon and ligament repair ... Four sizes are available, in ...
Medicine Products: